OnabotulinumtoxinA Bladder Injection Study

Inclusion Criteria: * Women and men, 18 years of age or older * Self-reported failed conservative care of behavioral modifications and/or oral medications for the treatment of OAB * Average urinary frequency of \> 8 voids per day as recorded on initial 3-day voiding diary * Self-reported bladder symptoms \> 3 months * Discontinued antimuscarinics/beta-3 agonists for \> 2 weeks prior to study enrollment. May restart antimuscarinics/beta-3 agonists if indicated \> 6 weeks after Botox injections. * Capable of giving informed consent * Capable and willing to follow all study-related procedures * Previous OnabotulinumtoxinA injection at least three months prior to study enrollment. Exclusion Criteria: * Pregnant or planning to become pregnant during study duration * Diagnosis of neurogenic bladder with the exception of highly functioning stroke patients * If a patient has had a previous neuromodulation device placed, it will have to be turned off for 2 weeks for a washout period and remain off throughout the study * Previous non-responders to onabotulinumtoxinA (BTX) therapy * Patient cannot be receiving percutaneous nerve stimulation (PTNS) therapy. If patient is receiving PTNS, they need to stop for 1 month prior to entering the study. * Refusal to self-catheterize or have indwelling catheter in the event of urinary retention * Use of investigational drug/device therapy within past 4 weeks * Participation in any clinical investigation involving or impacting gynecologic, urina…